News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Giuseppe Banna: Promising results for Telisotuzumab Vedotin in advanced NSCLC
Aug 27, 2024, 22:06

Giuseppe Banna: Promising results for Telisotuzumab Vedotin in advanced NSCLC

Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on X:

“The Phase II LUMINOSITY trial shows promising results for Telisotuzumab Vedotin in treating c-Met protein–overexpressing advanced NSCLC, especially in patients with high c-Met expression.”

Giuseppe Banna

Source: Giuseppe Banna/X

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

Authors: D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Goldman, Fedor Moiseenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih-Hsi Kuo, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, and Shun Lu.

Giuseppe Banna

Aaron S. Mansfield Alona Zer c-Met protein cancer Chih-Hsi Kuo Christina Baik Christine Ratajczak Chunling Liu D. Ross Camidge David Planchard Elena Filippova Ellen Bolotin Fedor Moiseenko Giuseppe Banna Hidehito Horinouchi Irfan Cicin Jair Bar Ji-Youn Han Jim Looman Jonathan Goldman Kazumi Nishino Kristof Cuppens LUMINOSITY trial Martha Li Mor Moskovitz Nathalie Daaboul Nicolas Girard NSCLC Nuran Katgi OncoDaily Oncology Pascale Tomasini Penelope Bradbury Peter Ansell Se-Hoon Lee Shang-Yin Wu Shobhit Baijal Shun Lu Summer Xia Telisotuzumab Vedotin Tudor Ciuleanu
Special Coverage
Celebrities
Jan 16, 2025, 17:18
Bob Uecker Dies at 90 from Small-Cell Lung Cancer
Insight
Jan 16, 2025, 16:45
The 2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents
Insight
Jan 16, 2025, 16:28
ACS CAN Report: High Costs Block Critical Follow-Up Tests for Breast Cancer
Blog
Jan 16, 2025, 16:20
Genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC - ASGO Education
Science
Jan 16, 2025, 16:10
Neoadjuvant therapy in patients with left-sided resectable pancreatic cancer
Blog
Jan 16, 2025, 16:05
David Wakeling: Alice’s Arc’s new research grant to some of the best minds in US paediatric cancer research
Science
Jan 16, 2025, 16:03
Estela Rodriguez: Updated analysis of CM816
Blog
Jan 16, 2025, 16:01
Elizabeth Ugwoma Awo-Ejeh: The Power of Showing Up - Closing the 10-Day Challenge
Career
Jan 16, 2025, 15:57
Elene Mariamidze: I finally got into the 2025 IASLC Academy
Insight
Jan 16, 2025, 15:50
The Gynaecology Course at the 17th BGICC
Insight
Jan 16, 2025, 15:49
Elvina Almuradova: Delighted to continue serving as a ESO Ambassador for Turkey
Blog
Jan 16, 2025, 15:46
Roupen Odabashian: Why do I see more young patients with cancer?